Amylyx Pharmaceuticals, Inc. director and officer Justin Klee filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 100,000 shares of common stock through Morgan Stanley Smith Barney LLC.
Key Highlights
- Proposed sale: Justin Klee, listed as both a director and officer of Amylyx Pharmaceuticals, intends to sell 100,000 shares of common stock.
- Aggregate market value: The proposed sale carries an aggregate market value of $2,950,000.00, according to the filing.
- Shares outstanding: The filing reports 128,562,904 shares of common stock outstanding.
- Shares acquired as Founders Shares: The 100,000 shares were acquired on January 13, 2014, from the issuer as Founders Shares.
- Prior sales in past three months: Klee sold 30,464 shares on September 10, 2026, for gross proceeds of $980,263.27.
- 10b5-1 plan adoption: The filing indicates a Rule 10b5-1 plan adoption date of May 11, 2026.
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker.
Justin Klee's Proposed Share Sale Under Rule 144 at Amylyx Pharmaceuticals
According to the Form 144 notice filed on November 9, 2026, Justin Klee, who holds both director and officer roles at Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), has provided notice of a proposed sale of 100,000 shares of the company's common stock. The approximate date of sale listed in the filing is November 9, 2026, with the transaction to be executed on the NASDAQ exchange through Morgan Stanley Smith Barney LLC.
The filing states that the 100,000 shares subject to the proposed sale were originally acquired on January 13, 2014, through a Founders Shares transaction with the issuer, with payment made on the same date and listed as "N/A" for nature of payment. The aggregate market value attributed to the proposed sale is $2,950,000.00. As of the filing, the company reported 128,562,904 shares of common stock outstanding.
In the section covering securities sold during the past three months, the filing discloses that Klee sold 30,464 shares of common stock on September 10, 2026, generating gross proceeds of $980,263.27. The notice also indicates that the sale is being conducted in reliance on a Rule 10b5-1 written trading plan adopted on May 11, 2026. By signing the form, Klee represented, as of the plan adoption date, that he was not aware of any material adverse information regarding the issuer's current and prospective operations that had not been publicly disclosed.
What Was Disclosed
Amylyx Pharmaceuticals director and officer Justin Klee filed a Form 144 on November 9, 2026, disclosing the proposed sale of 100,000 Founders Shares valued at $2,950,000.00, executed under a Rule 10b5-1 plan adopted May 11, 2026, with Morgan Stanley Smith Barney LLC as broker.




Please wait processing your request...